نتایج جستجو برای: Fulvestrant

تعداد نتایج: 782  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Neill Patani Anita K Dunbier Helen Anderson Zara Ghazoui Ricardo Ribas Elizabeth Anderson Qiong Gao Roger A'hern Alan Mackay Justin Lindemann Robert Wellings Jill Walker Irene Kuter Lesley-Ann Martin Mitch Dowsett

PURPOSE Endocrine therapies include aromatase inhibitors and the selective estrogen receptor (ER) downregulator fulvestrant. This study aimed to determine whether the reported efficacy of fulvestrant over anastrozole, and high- over low-dose fulvestrant, reflect distinct transcriptional responses. EXPERIMENTAL DESIGN Global gene expression profiles from ERα-positive breast carcinomas before a...

2016
Qingyuan Zhang Zhimin Shao Kunwei Shen Li Li Jifeng Feng Zhongsheng Tong Kangsheng Gu Xiaojia Wang Binghe Xu Guofang Sun Huifang Chen Yuri Rukazenkov Zefei Jiang

The international CONFIRM study showed that fulvestrant 500 mg improved progression-free survival (PFS) vs fulvestrant 250 mg in postmenopausal women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer (LA/MBC). In this randomized, double-blind study, postmenopausal Chinese women with ER-positive LA/MBC and progression after endocrine therapy received fulvestrant 500 ...

Journal: :The Journal of pharmacology and experimental therapeutics 2011
James M Fitts Robert M Klein C Andrew Powers

Tamoxifen is a selective estrogen receptor (ER) modulator, but it is also a deactivating ligand for estrogen-related receptor-γ (ERRγ) and a full agonist for the G protein-coupled estrogen receptor (GPER). Fulvestrant is a selective ER down-regulator that lacks agonist effects on ERα/ERβ, is inactive on ERRγ, but acts as a full agonist on GPER. Fulvestrant effects on tamoxifen actions on uterin...

2017
Hiroji Iwata Seock-Ah Im Norikazu Masuda Young-Hyuck Im Kenichi Inoue Yoshiaki Rai Rikiya Nakamura Jee Hyun Kim Justin T. Hoffman Ke Zhang Carla Giorgetti Shrividya Iyer Patrick T. Schnell Cynthia Huang Bartlett Jungsil Ro

PURPOSE To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy-resistant metastatic breast cancer. PATIENTS AND METHODS The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a double-blind phase III study, included 521 patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic bre...

2014
Neill Patani Anita K. Dunbier Helen Anderson Zara Ghazoui Ricardo Ribas Elizabeth Anderson Qiong Gao Roger A'hern Alan Mackay Justin Lindemann Robert Wellings Jill Walker Irene Kuter Mitch Dowsett

Purpose: Endocrine therapies include aromatase inhibitors and the selective estrogen receptor (ER) downregulator fulvestrant. This study aimed to determine whether the reported efficacy of fulvestrant over anastrozole, and highover low-dose fulvestrant, reflect distinct transcriptional responses. Experimental Design:Global gene expression profiles from ERa-positive breast carcinomas before and ...

2014
Sonia C. Dolfi Adriana V. Jäger Daniel J. Medina Bruce G. Haffty Jin-Ming Yang Kim M. Hirshfield

The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulvestrant on MDM2 expression and sensitivity of estrogen receptor positive human breast cancer cell lines to chemotherapeutics. Fulvestrant down-regulated MDM2 through increased protein turnover. Ful...

Journal: :The Journal of biological chemistry 2006
Xinghua Long Kenneth P Nephew

The antiestrogen fulvestrant (ICI 182,780) causes immobilization of estrogen receptor-alpha (ERalpha) in the nuclear matrix accompanied by rapid degradation by the ubiquitin-proteasome pathway. In this study we tested the hypothesis that fulvestrant induces specific nuclear matrix protein-ERalpha interactions that mediate receptor immobilization and turnover. A glutathione S-transferase (GST)-E...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Yuki Ishii Luena Papa Urvashi Bahadur Zhenyu Yue Julio Aguirre-Ghiso Toshi Shioda Samuel Waxman Doris Germain

PURPOSE Fulvestrant is known to promote the degradation of the estrogen receptor (ER) in the nucleus. However, fulvestrant also promotes the aggregation of the newly synthesized ER in the cytoplasm. Accumulation of protein aggregates leads to cell death but this effect is limited as a result of their elimination by the proteasome. We tested whether combining fulvestrant with the proteasome inhi...

2016
Brendon Ladd Anne Marie Mazzola Teeru Bihani Zhongwu Lai James Bradford Michael Collins Evan Barry Anne U. Goeppert Hazel M. Weir Kelly Hearne Jonathan G. Renshaw Morvarid Mohseni Elaine Hurt Sanjoo Jalla Haifeng Bao Robert Hollingsworth Corinne Reimer Michael Zinda Stephen Fawell Celina M. D'Cruz

Although endocrine therapy is successfully used to treat patients with estrogen receptor (ER) positive breast cancer, a substantial proportion of this population will relapse. Several mechanisms of acquired resistance have been described including activation of the mTOR pathway, increased activity of CDK4 and activating mutations in ER. Using a patient derived xenograft model harboring a common...

2016
Ameet K. Mishra Annelie Abrahamsson Charlotta Dabrosin

The estrogen receptor-alpha (ERα) is used as a predictive marker for anti-estrogen therapy in breast cancer patients. In addition to aromatase inhibitors, ERα can be targeted at the receptor level using the receptor modulator tamoxifen or by the pure anti-estrogen fulvestrant. The role of the second ER, ER-beta (ERβ), as a therapeutic target or prognostic marker in breast cancer is still elusiv...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید